Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Stevanato Group to Report First Quarter 2023 Financial Results on May 4, 2023


Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2023 on Thursday, May 4, 2023, at 6:30 a.m. (ET).

Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 4, 2023 to discuss financial results. During the call, management will refer to a slide presentation which will be available at 6:30 a.m. (ET) on the day of the call on the "Financial Results" page under the Company's Investor Relations section of its website.

Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link:
http://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=4544003&linkSecurityString=514976446

Webcast: A live, listen-only webcast of the call will be available at the following link:
https://87399.choruscall.eu/links/stevanato230504.html

Dial in: Those who are unable to pre-register may dial in by calling:

       

Italy:

+39 02 802 09 11

       

United Kingdom:

+44 1 212 818004

       

United States:

+1 718 705 8796

       

United States Toll Free:

+1 855 265 6958

Replay:

The webcast will be archived for three months on the Company's Investor Relations section of its website at:
https://ir.stevanatogroup.com/financial-results.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. For more information, please visit www.stevanatogroup.com.


These press releases may also interest you

at 23:18
Sungrow, the global leading PV inverter and energy storage system provider, exhibited its cutting-edge and comprehensive renewable energy solutions at the World Future Energy Summit (WFES) 2024. Notably, Sungrow has achieved a remarkable milestone by...

at 23:16
The emergence of Generative AI (GenAI) has led to the widespread use of AI assistants across various sectors including business environments, education, healthcare, legal and accounting fields, banking, and even migration into embedded and industrial...

at 23:05
TSX VENTURE COMPANIES BULLETIN V2024-1116 C-COM SATELLITE SYSTEMS INC.  ("CMI")BULLETIN TYPE:  Declaration of DividendBULLETIN DATE:  April 17, 2024TSX Venture Tier 1 Company The Issuer has declared the following dividend:  Dividend per Share: ...

at 23:00
WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Ocugen, Inc. between May 8, 2020 and April 1, 2024, both dates inclusive (the "Class Period"). A class...

at 22:52
CO280 and Aker Carbon Capture have signed a Memorandum of Understanding (MoU) agreement with Microsoft to explore...

at 22:34
OKX, a leading Web3 technology company, has issued updates for April 17, 2024. OKX Partners with OverProtocol to Launch Airdrop Event...



News published on and distributed by: